TY - JOUR
T1 - Determinants of recovery from post-COVID-19 dyspnoea
T2 - analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls
AU - Zheng, Bang
AU - Vivaldi, Giulia
AU - Daines, Luke
AU - Leavy, Olivia C.
AU - Richardson, Matthew
AU - Elneima, Omer
AU - McAuley, Hamish J. C.
AU - Shikotra, Aarti
AU - Singapuri, Amisha
AU - Sereno, Marco
AU - Saunders, Ruth M.
AU - Harris, Victoria C.
AU - Houchen-Wolloff, Linzy
AU - Greening, Neil J.
AU - Pfeffer, Paul E.
AU - Hurst, John R.
AU - Brown, Jeremy S.
AU - Shankar-Hari, Manu
AU - Echevarria, Carlos
AU - De Soyza, Anthony
AU - Harrison, Ewen M.
AU - Docherty, Annemarie B.
AU - Lone, Nazir
AU - Quint, Jennifer K.
AU - Chalmers, James
AU - Ho, Ling-Pei
AU - Horsley, Alex
AU - Marks, Michael
AU - Poinasamy, Krisnah
AU - Raman, Betty
AU - Heaney, Liam G.
AU - Wain, Louise V.
AU - Evans, Rachael A.
AU - Brightling, Christopher E.
AU - Martineau, Adrian R.
AU - Sheikh, Aziz
AU - PHOSP-COVID Collaborative Group
N1 - Funding Information:
COVIDENCE UK: We thank all participants of COVIDENCE UK, and the following organisations who supported study recruitment: Asthma UK/British Lung Foundation, the British Heart Foundation, the British Obesity Society, Cancer Research UK, Diabetes UK, Future Publishing, Kidney Care UK, Kidney Wales, Mumsnet, the National Kidney Federation, the National Rheumatoid Arthritis Society, the North West London Health Research Register (DISCOVER), Primary Immunodeficiency UK, the Race Equality Foundation, SWM Health, the Terence Higgins Trust, and Vasculitis UK. PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care.
Copyright:
© 2023 The Author(s). Published by Elsevier Ltd.
PY - 2023/6
Y1 - 2023/6
N2 - Background: The risk factors for recovery from COVID-19 dyspnoea are poorly understood. We investigated determinants of recovery from dyspnoea in adults with COVID-19 and compared these to determinants of recovery from non-COVID-19 dyspnoea. Methods: We used data from two prospective cohort studies: PHOSP-COVID (patients hospitalised between March 2020 and April 2021 with COVID-19) and COVIDENCE UK (community cohort studied over the same time period). PHOSP-COVID data were collected during hospitalisation and at 5-month and 1-year follow-up visits. COVIDENCE UK data were obtained through baseline and monthly online questionnaires. Dyspnoea was measured in both cohorts with the Medical Research Council Dyspnoea Scale. We used multivariable logistic regression to identify determinants associated with a reduction in dyspnoea between 5-month and 1-year follow-up. Findings: We included 990 PHOSP-COVID and 3309 COVIDENCE UK participants. We observed higher odds of improvement between 5-month and 1-year follow-up among PHOSP-COVID participants who were younger (odds ratio 1.02 per year, 95% CI 1.01–1.03), male (1.54, 1.16–2.04), neither obese nor severely obese (1.82, 1.06–3.13 and 4.19, 2.14–8.19, respectively), had no pre-existing anxiety or depression (1.56, 1.09–2.22) or cardiovascular disease (1.33, 1.00–1.79), and shorter hospital admission (1.01 per day, 1.00–1.02). Similar associations were found in those recovering from non-COVID-19 dyspnoea, excluding age (and length of hospital admission). Interpretation: Factors associated with dyspnoea recovery at 1-year post-discharge among patients hospitalised with COVID-19 were similar to those among community controls without COVID-19.
AB - Background: The risk factors for recovery from COVID-19 dyspnoea are poorly understood. We investigated determinants of recovery from dyspnoea in adults with COVID-19 and compared these to determinants of recovery from non-COVID-19 dyspnoea. Methods: We used data from two prospective cohort studies: PHOSP-COVID (patients hospitalised between March 2020 and April 2021 with COVID-19) and COVIDENCE UK (community cohort studied over the same time period). PHOSP-COVID data were collected during hospitalisation and at 5-month and 1-year follow-up visits. COVIDENCE UK data were obtained through baseline and monthly online questionnaires. Dyspnoea was measured in both cohorts with the Medical Research Council Dyspnoea Scale. We used multivariable logistic regression to identify determinants associated with a reduction in dyspnoea between 5-month and 1-year follow-up. Findings: We included 990 PHOSP-COVID and 3309 COVIDENCE UK participants. We observed higher odds of improvement between 5-month and 1-year follow-up among PHOSP-COVID participants who were younger (odds ratio 1.02 per year, 95% CI 1.01–1.03), male (1.54, 1.16–2.04), neither obese nor severely obese (1.82, 1.06–3.13 and 4.19, 2.14–8.19, respectively), had no pre-existing anxiety or depression (1.56, 1.09–2.22) or cardiovascular disease (1.33, 1.00–1.79), and shorter hospital admission (1.01 per day, 1.00–1.02). Similar associations were found in those recovering from non-COVID-19 dyspnoea, excluding age (and length of hospital admission). Interpretation: Factors associated with dyspnoea recovery at 1-year post-discharge among patients hospitalised with COVID-19 were similar to those among community controls without COVID-19.
KW - Cohort
KW - COVID-19
KW - Dyspnoea
KW - Long COVID
KW - Recovery
UR - http://www.scopus.com/inward/record.url?scp=85153861058&partnerID=8YFLogxK
U2 - 10.1016/j.lanepe.2023.100635
DO - 10.1016/j.lanepe.2023.100635
M3 - Article
C2 - 37261214
AN - SCOPUS:85153861058
SN - 2666-7762
VL - 29
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
M1 - 100635
ER -
